Cocrystal Pharma, Inc. (COCP) Misses Q2 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Cocrystal Pharma, Inc. (COCP) Misses Q2 EPS by 21c

Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs

August 15, 2022 8:00 AM EDT

Planned Phase 2a study design with orally administered CC-42344 for the treatment of pandemic and seasonal influenza AReported pharmacokinetic (PK) data from the single ascending dose portion of its Phase 1 study with CC-42344 supporting once-daily dosingCollaborated with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the potential of the Companys COVID-19 protease inhibitors and subsequently expanded the collaboration to support a scale-up synthesis of these inhibitorsInitiated API (Active Pharmaceutical Ingredient) synthesis and process chemistry... More